NCT04857866已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®27564 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Xencor, Inc.
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent adverse events, graded by CTCAE Version 5.0
研究概览
简要总结
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.
详细描述
This study will determine the safety and tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of XmAb27564 in normal healthy volunteers. XmAb27564 is an engineered IL-2 mutein being developed for autoimmune diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Total body weight 50.0 to 100.0 kg and body mass index (BMI) 19.0 to 35.0 kg/m2
- •In good general health with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease.
- •A nonsmoker for at least 12 weeks preceding screening
- •Female subjects of childbearing potential must agree to use a highly effective method of birth control during and for 45 days after administration of investigational product (IP).
- •Fertile male and female subjects must be willing to practice a highly effective method of birth control during and for 45 days after administration of IP and agree not to donate sperm from screening through 45 days after administration of IP.
排除标准
- •Subjects who have a clinically relevant history or presence of diseases or disorders that would pose a significant risk to subject's safety or significantly interfere with the study evaluation, procedures, or completion
- •Subjects with history of any cardiovascular event
- •Subjects with vital sign values outside the normal ranges
- •Subjects who are positive for MTB QuantiFERON, hepatitis B surface antigen, hepatitis C virus antibody, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) by polymerase chain reaction (PCR)/antigen, or human immunodeficiency virus Type I or Type II tests at screening
- •Subjects with signs or symptoms consistent with active viral infection
- •Subjects with baseline eosinophil elevation or a history of urticaria, asthma, allergic dermatitis, food allergy or eosinophilic esophagitis
- •Subjects who have evidence of any bacterial, viral, parasitic, or systemic fungal infections requiring treatment within the 21 days prior to randomization; or hospitalization due to infection within 3 months prior to randomization
- •Subjects who have had any prior investigational treatment with interleukin 2 (IL-2) therapies or have received any investigational agent within five half-lives of the study drug
- •Subjects with a known or suspected sensitivity to products from mammalian cell lines
- •Subjects who have received live vaccines ≤ 2 months prior to screening or any vaccine within the past 14 days
研究组 & 干预措施
Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F
Experimental
干预措施: XmAb27564 (Drug)
Single Ascending Dose - Placebo Subcutaneous injection of placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of treatment-emergent adverse events, graded by CTCAE Version 5.0
时间窗: Up to Day 45
次要结局
- PK: Measurement of Cmax(45 Days)
- PK: Measurement of Tmax(45 Days)
- PD: Measurement of Change in Number of Regulatory T Cells(45 Days)
- PK: Maximum Observed Drug Concentration (Cmax) of XmAb27564 after a single dose(45 Days)
- PK: Measurement of T1/2(45 Days)
- PK: Time to Decrease in Concentration by Half (T1/2) of XmAb27564 after a single dose, due to elimination(45 Days)
- PK: Time to Maximum Plasma Concentration (Tmax) of XmAb27564 after a single dose(45 Days)
- PK: Area Under the Drug Concentration - Time Curve from Zero to the End of Observation(45 Days)
- PD: Measurement of Change in Number of Natural Killer Cells (NK Cells) in Blood(45 Days)
- PD: Measurement of Cytokines in Blood(45 Days)
- PD: Measurement of Change in Number of Subsets of Conventional T Cells in Blood(45 Days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy VolunteersHealthy VolunteerNCT01597947Achaogen, Inc.50
已完成
1 期
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)Heart Failure With Reduced Ejection FractionNCT04210375Salubris Biotherapeutics Inc14
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy VolunteersPostoperative PainChronic PainNCT04110886Sichuan Haisco Pharmaceutical Group Co., Ltd120
已完成
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SutezolidTuberculosis, PulmonaryTuberculosisNCT03199313Global Alliance for TB Drug Development32
已完成
1 期
Evaluation of 626 in Healthy Adult SubjectsHealthy Subjects (HS)NCT06674525Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.50